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“Psychedelic substances, if they are used in proper ways, are very helpful for mankind.” Albert 
Hoffmann 
The word ‘psychedelic’ derives from the Greek terms for mind – psyche – and ‘delos’ which 
means ‘clear, manifest’ so in essence psychedelic drugs can be seen as the prototype ‘window 
on the mind’ concept. The term was originally coined in the 1950s to describe lysergic acid 
diethylamide (LSD), mescaline and other hallucinogens, drugs that profoundly alter human 
experience.  These have subsequently been show to act primarily as agonists at the 5-
HT2A receptor in the brain.  Research into the therapeutic potential and mechanisms of action 
of psychedelic and related drugs peaked in the late 1960’s but then stagnated for 50 years 
after the 1971 UN Psychotropics Convention made psychedelic research with humans almost 
impossible to carry out (Kyzar et al, 2017).    
Recently however, this area is experiencing a renaissance as drugs often associated with 
recreational use – such as LSD, ketamine and cannabis/cannabinoids – have been shown to 
have therapeutic potential in a range of disorders such as treatment-resistant depression, 
suicidal ideation and some paediatric epilepsies.  Further, recent pilot studies suggest that 
MDMA as well as the classic psychedelics, LSD and psilocybin, may contribute to the 
pharmacopeia for post-traumatic stress disorder (PTSD) and other difficult to treat psychiatric 
disorders.  Research has also been stimulated by functional neuroimaging studies of single 
doses of psychedelics showing that they produce widespread changes in brain connectivity as 
well as profound alterations to perception and cognition. At the same time, as one would 
expect from a relatively fledgling area, many questions remain about mechanisms of action, 
safety and efficacy.  These include what type of psychological therapies best combine with 
which type of psychedelic drug, whether some types of drug have benefits even without 
psychological treatment, what the optimal doses are, from single dose through to 
intermittent or repeated dosing.  The current renaissance in empirical psychedelic research 
stimulated this Special Issue of Psychopharmacology.  The articles are grouped into three 
sections: Clinical efficacy and clinical issues; Effects and Mechanisms of action; Regulation and 
history.  
Clinical efficacy and clinical issues 
Four studies address the promising new therapeutic potential of MDMA, ketamine, LSD and 
cannabis for conditions ranging from PTSD to treatment-resistant depression (TRD).  Building 
on recent pilot studies supporting a therapeutic potential of MDMA as an adjunct to 
psychotherapy in post-traumatic stress disorder PTSD, Pitts and colleagues review the 
preclinical and clinical evidence concerning the individual S(+) and R(-) enantiomers that 
comprise (+) MDMA.  They conclude that R(-)-MDMA may have a better side-effect profile 
than S(+), and that future studies should directly compare the potential therapeutic 
advantages of both enantiomers in humans.  Another drug, ketamine, administered 
intravenously (iv), intramuscularly (im) or intra-nasally (in), has been used with great success 
as a rapid-onset treatment for TRD and associated conditions. de Gioannis et al conducted a 
retrospective review of clinical records of patients receiving long-term oral ketamine as an 
adjunctive treatment of PTSD and TRD, and concluded that long-term oral administration is 
also a viable option.  Psilocybin shows promise in the treatment of TRD.  Robin Carhart-Harris 
et al report a 1-week to 6 months follow up of TRD patients who were given two separate 
single doses of psilocybin with psychological support as part of an earlier open-label pilot 
study. The investigators report that marked symptom improvements observed at 5 weeks 
post-treatment were still significant at 6 months, suggesting a full double-blind trial would be 
warranted. Finally, cannabinoids have been proposed for a range of conditions.  Yet, concerns 
have been raised about the potential for misuse or problematic use, addressed here in a large 
study conducted in Canada by Martel et al.    After baseline measures, 265 patients were 
initiated onto cannabinoid treatment and were re-assessed every 3 months for a year.  Most 
patients showed no problematic use and the roughly 25% who did were more likely to have 
had a past-year history of substance misuse and previous psychiatric problems.   Martel et al 
thoughtfully discuss the clinical and policy implications of these findings for cannabinoid 
treatments. 
__________________________________________________________________________ 
Mechanisms of action and effects 
Nine articles focus on the effects of psychedelic and the mechanisms underpinning these.   
Retrieval of a memory can return it to a plastic, malleable state, which may provide an 
opportunity to ‘rewrite’ aberrant, unwanted memories. For example, a hallmark symptom of 
PTSD are involuntary memory intrusions that are related to the trauma experience.  Or again, 
substance use disorders (SUDs) are associated with maladaptive memories which can direct 
the individual’s attention to drug-related rather than natural rewards in the environment.  
Fattore et al’s thoughtful review focuses on one process for changing labile memories via 
reconsolidation.  They review the effects of ketamine and cannabinoids on both traumatic 
and appetitive maladaptive memories and suggest that both drugs act on a process termed 
‘metaplasticity’.  They argue that the ability to change such memories offers a novel 
intervention for PTSD and SUD.   
Hudson and colleagues review both preclinical and clinical evidence on the influence of 
different phytocannabinoids on emotional memory processing (EMP).  They conclude that the 
mechanisms underpinning these effects are the actions of cannabinoids within the ventral 
hippocampus and associated corticolimbic structures which modulate EMP via changes in 
mesolimbic dopamine activity, salience attribution and signal transduction pathways.  
Two empirical studies then directly address issues of how the effects of psychedelics may be 
mediated by changes in emotional processing.  Using a sensitive dynamic facial emotion 
recognition task, Stroud et al. assessed individuals with TRD before and after two separate 
doses of psilocybin and compared them with healthy controls at similar time points. 
Psilocybin improved the speed of recognising facial emotions in the depressed group so that 
they were as fast as controls after treatment, and this speed increase correlated with a 
reduction in anhedonia over the same time period.  Dolder, Liechti and colleagues used a 
facial emotion recognition task (FERT) to compare the effects of three stimulants (MDMA, 
methylphenidate and modafinil). They found that MDMA was the only one of the three drugs 
which impaired fear recognition and increased mislabelling of emotions as happy.  Whereas 
all three drugs produced similar hemodynamic and adverse effects, MDMA had distinct 
subjective, emotional, sexual and endocrine effects from other two drugs.  
Kim Kuypers and colleagues report how the 5-HT2A receptor antagonist, ketanserin affects 
responses to a single dose of MDMA on responses to emotional sounds and biases towards 
emotional and social stimuli. MDMA reduced the arousal induced by negative sounds and 
ketanserin blocked this effect, extending previous findings using only visual emotional stimuli.  
Tomas Palenicek et al  investigated the effects of a single dose of psilocybin on auditory event-
related potentials (ERPs) and mismatch negativity (MMN).  Pre-attentive cognition (MMN) 
was unaffected whilst processing in the early perceptual level (N100) and in higher-order 
cognition (P300) was significantly disrupted by psilocybin. They draw out implications of these 
findings for the role of 5-HT2A receptors in disrupted information processing  
Kaelen et al take a mixed qualitative/quantitative approach to exploring the potential role of 
music in psychedelic therapy.  They qualitatively assessed interviews with individuals 
diagnosed with TRD who had taken part in a pilot study of psilocybin as an adjunct to 
psychotherapy, which included music.  They report that the nature of the experience of music 
was associated with reductions in depressed mood 7 days after the drug.  
Dose-response studies of psychedelic effects in humans are still rare.  In a timely addition, 
Theresa Carbonaro and her colleagues report a study which compares 3 separate doses of 
psilocybin with dextromethorphan (DXM).  Both drugs produced similar physiological effects 
and similar psychomotor impairments.  In contrast, psilocybin produced relatively greater 
visual, mystical-type, insightful, and musical experiences whereas DXM producing greater 
disembodiment.  
There are many anecdotal reports that psychedelic experiences induce profound changes in 
consciousness and insight .  Schmid et al explored this by assessing mystical-like experiences, 
well-being and personality at three time points: before and 1 and 12 months after one dose 
of LSD was administered in a controlled laboratory setting.  Ten of the 14 participants 
reported positive, long lasting subjective effects of LSD 12months after the experience, rating 
LSD in the top 10 most meaningful experiences of their lives.   In a brief commentary, Carhart-
Harris et al suggest that psychedelic drugs may exert therapeutic effects via inducing a sense 
of ‘connectedness’ and suggests ways this might be tested empirically.  
_____________________________________________________________________ 
Regulation and histories 
A commentary by the psychiatrist Ben Sessa describes a ‘psychedelic renaissance’ involving 
both classic psychedelics such as LSD and psilocybin but also the entactogen MDMA.  
Although he describes “heroic steps forward”, he sees these taking place slowly “on the back 
of an elephant” rather than with the speed of a space rocket and outlines various regulatory 
and societal impediments which need to be overcome before carrying out  research with 
psychedelics.  The Multidisciplinary Association for Psychedelic Studies (MAPS) have a long 
history of supporting this area of research and Feduccia et al describe how MAPS have 
developed their particular program on MDMA-assisted psychotherapy for PTSD.   Positive 
results of recent Phase 2 trials provide the rationale for Phase 3 multi-site trials that are due 
to begin in 2018.  
A timely review of the abuse potential of kratom is provided by Jack Henningfield and 
colleagues. Kratom, a plant of the species Mitragyna speciosa, has a long history of use in for 
pain conditions and in the last century for assisting opiate withdrawal.  Currently there is 
controversy about whether the US Drug Enforcement Administration (DEA) and Food and 
Drug Administration (FDA) should put it in Schedule 1 of the Controlled Substance Act (CSA).  
Henningfield et al examine kratom in light of the 8 factors required by the CSA to determine 
abuse potential.  They conclude that some form of scheduling may be warranted but placing 
kratom in Schedule 1 would effectively ban it and create both public health problems for users 
and barriers for future research.  
The regulatory history of research on LSD in the US from 1949 to 1987 is the topic of the last 
paper in this Special Issue. Bronson  describes how regulations changed over the years about 
scientific standards of clinical drug research, standards which many of the 1960s LSD studies 
struggled to meet.  She concludes that these early studies should be viewed as providing pilot 
data on safety and efficacy and at best, generating hypotheses that could be tested under 
modern scientific and regulatory standards. 
Overall, the articles in this Special Issue illustrate the breadth and diversity of research on 
psychedelic drugs, and how,  in terms of high scientific quality, the area is now experiencing 
a naissance more than a renaissance.    Regulatory changes that facilitate rather than obstruct 
research with these compounds will significantly aid progress in this field. 
